New Zealand throws out Canesten reclassification
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
New Zealand’s Medsafe has rejected a down-scheduling proposal from Bayer to reclassify its Canesten Plus antifungal cream from pharmacist-only to pharmacy-only medicine.